微移植巩固治疗对完全缓解后急性髓系白血病患者的疗效分析

目的:观察微移植在急性髓系白血病(AML)中的疗效与安全性.方法:回顾性分析2014年7月至2019年10月接受微移植作为巩固治疗的13例成人AML患者的临床资料,随访观察微移植治疗的不良反应与疗效.结果:13例微移植患者中有8例仍处于完全缓解状态,5例患者微移植后复发,其中1例再诱导缓解后行脐血微移植.目前13例均处...

Efficacy of Micro-Transplantation Consolidation Therapy for Patients with Acute Myeloid Leukemia after Complete Remission

Objective:To investigate the efficacy and safety of micro-transplantation in acute myeloid leukemia(AML).Methods:The clinical data of 13 adult AML patients who received micro-transplantation as consolidation therapy from July 2014 to October 2019 was retrospectively analyzed,and the adverse reactions and efficacy of micro-transplantation were followed up.Results:Eight patients received micro-transpantation were still in complete remission,5 patients relapsed after micro-transplantation,1 of them received umbilical cord blood micro-transplantation after remission by reinduction,and all of the 13 patients have survived till now.The median overall survival time was 13 months,and the median relapse-free survival time was 12 months.All 13 patients developed grade 2-4 hematological adverse reactions.The median recovery time of neutrophils and platesets was 13(11-15)and 15(13-17)days,respectively.None of the 13 patients developed acute or chronic graft versus host disease.Twelve patients suffered from different infections,however,there were no senous organ function injury complications happened.Conclusion:The micro-transplomtation of HLAincompatible stem cells derived from peripheral blood or umbilical and blood is an effective regimen for the consolidation therapy of AML,especially for the patients suffered from low and moderate risk of AML or the aged AML patients.